Navigation Links
Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting

pment for the treatment of advanced ovarian cancer and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in clinical development in myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

This press release contains "forward-looking" statements, including statements regarding the potential for TELCYTA to treat one or more types of cancer. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, that none of Telik's product candidates have been determined to be safe or effective in humans or been approved for marketing, clinical trials of Telik's product candidates may take several years to complete and may not be successful, success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful and interim results of clinical trials do not necessarily predict final results. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the year ended December 31, 2006. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

NOTE: TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.

CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, +1-650-845-7728, or '"/>




Page: 1 2 3

Related medicine technology :

1. Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/13/2014)... 12, 2014 Mindray Medical International Limited ("Mindray", ... and marketer of medical devices worldwide, today announced shareholder ... held in Hong Kong on ... shareholders voted to re-elect incumbent directors Li Xiting and ... shareholders did not re-elect Peter Wan as ...
(Date:12/13/2014)... INDIANAPOLIS , Dec. 12, 2014  Novo Nordisk, a ... (CGRT), today announced a multi-year extension of their partnership, that ... No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by ... Kimball, 29, from Camarillo, California ... in the history of INDYCAR to win a race at ...
(Date:12/13/2014)... Dec. 11, 2014 Research and Markets ... of the "China Chemical Pharmaceutical Industry Report, ... http://photos.prnewswire.com/prnh/20130307/600769 ... preparation and active pharmaceutical ingredient (API), and the ... generally higher than that of the API over ...
Breaking Medicine Technology:Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7China Chemical Pharmaceutical Industry Report, 2013-2016 2China Chemical Pharmaceutical Industry Report, 2013-2016 3
... 18 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) ... is developing a potential cancer drug,that seeks to ... a pre-clinical product being developed by Aida,s Shanghai,Qiaer ... the,function of extracted fragments of Vasostatin, an inhibitor ...
... CARLSBAD, Calif., April 18 Isis,Pharmaceuticals, Inc. ... of two studies,designed to assess the impact ... Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB),Conference ... in a poster,entitled "Antisense Inhibition of Apolipoprotein ...
Cached Medicine Technology:Aida Announces New Anti-Cancer Drug Under Development 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 3Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 4
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. ... fast approaching, a new study reveals that states that routinely ... drunk drivers on their roads. The finding suggests that ... able to deter inebriated revelers from getting behind the wheel ... being passed regarding drinking and driving," said study lead author ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... Boston, MA (PRWEB) December 15, 2014 ... health management solutions, announced today that it has ... for Quality Assurance (NCQA) for its Disease Management ... obstructive pulmonary disease (COPD), coronary heart disease and ... accreditation from NCQA for Health Dialog’s Disease Management ...
(Date:12/15/2014)... 2014 Emergo Group, Inc., a medical ... in North and South America, Europe, the Middle East, ... participants for its 2015 Medical Device Industry Survey. Each ... upcoming business and market trends as well as regulatory ... targets areas including:, , Overall prospects ...
(Date:12/15/2014)... For the second year in a row, Bird Rock ... 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak came in ... 10. This is the first year that any roaster made ... on quality, value, and other aspects, including certifications and distinct ... and at $17.99 for 12-ounces, was also the most affordable ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... large proportion of Medicare expenditures for nursing home residents ... aggressive treatments that may be avoidable and of limited ... Institute for Aging Research, an affiliate of Harvard Medical ... Archives of Internal Medicine on Jan. 10, 2011. ...
... January 10, 2011 -- Previous research regarding the association ... later life suggests that mild to moderate alcohol consumption ... research has been conducted on subjects already rather elderly ... published in the December issue of the Journal ...
... MONDAY, Jan. 10 (HealthDay News) -- The H1N1 swine flu ... a vaccine that can protect people against multiple strains of ... were infected with the H1N1 virus and recovered had a ... variety of flu strains. The virus matched typical influenza ...
... MONDAY, Jan. 10 (HealthDay News) -- Patients given cholesterol-lowering drugs ... the brain may be at an increased risk of having ... well-known that statins help reduce the risk of heart disease ... in the brain. However, whether statins also benefit patients who ...
... quintessentially masculine, women in their fertile phase are more ... paired with George Clooney types. But women with ... their partners, a recent study co-authored by a University ... man,s intelligence has no effect on the extent to ...
... found that a protein that plays an important role in ... additional mechanisms that cause it to promote atherosclerosis, or clogging ... issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology ... antioxidant therapies have not yielded more positive results. ...
Cached Medicine News:Health News:Aggressive care raises Medicare costs in end-stage dementia 2Health News:Aggressive care raises Medicare costs in end-stage dementia 3Health News:Abstinence, heavy drinking, binge drinking associated with increased risk of cognitive impairment 2Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2Health News:Statins May Be Harmful After Stroke 2Health News:Statins May Be Harmful After Stroke 3Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Protein thought to protect against oxidative stress also promotes clogging of arteries 2
Stainless Steel. Sterile. 2 pieces/box...
... attributes of the IMMULITE 2000, the IMMULITE ... Logic Driven Incubation (LDI). Using a newly ... be formatted for optimal performance with the ... assays, such as Siemens Diagnostics' cardiac biomarkers ...
... The SMS is a robotic sample feeder that ... systems via a robotic arm and the SMS ... 200 tubes and compatibility with clinical chemistry system ... make the SMS a practical and affordable solution ...
The properties of titanium alloy have been combined with a uniquely designed reverse radial tapping flute to produce a state-of-the-art fracture fixation system....
Medicine Products: